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Concise report
Effect of allopurinol on all-cause mortality in adults
with incident gout: propensity scorematched
landmark analysis
Chang-Fu Kuo1,2, Matthew J. Grainge3, Christian Mallen4, Weiya Zhang1 and
Michael Doherty1
Abstract
Objective. To examine the association between allopurinol use and all-cause mortality for patients with
incident gout.
Methods. We compared all-cause mortality in incident gout patients who received allopurinol for at least
6 months within the exposure window (1 year or 3 years) with those who did not, using the UK Clinical
Practice Research Data-link. Landmark analysis was used to account for immortal time bias and propen-
sity score matching was used to control for potential effects of known confounders.
Results. Of 23 332 incident gout patients identified, the propensity scorematched cohorts contained
1016 patients exposed to allopurinol on the date 1 year from diagnosis (landmark date) and 1016 allo-
purinol non-users. Over a median follow-up period of 10 years after the landmark date, there were 437
allopurinol users and 443 allopurinol non-users who died during follow-up. Allopurinol users and non-users
had similar risk for all-cause mortality (hazard ratio 0.99; 95% CI 0.87, 1.12). In the 3-year landmark
analysis, 3519 allopurinol users (1280 died) were compared with 3519 non-users (1265 died). The
hazard ratio for all-cause mortality was 1.01 (95% CI 0.92, 1.09).
Conclusion. This propensity scorematched landmark analysis in a population of incident gout patients in
the UK primary care setting found a neutral effect on the risk of all-cause mortality. Our study provides
reassurance about the prescription of allopurinol for gout patients early in their disease course to prevent
untoward consequences of chronic uncontrolled hyperuricaemia. However, whether higher than the com-
monly used dose of allopurinol could influence mortality remains to be determined.
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Rheumatology key messages
. Allopurinol is the most commonly used urate-lowering agent for long-term management of chronic gout.
. Allopurinol use in the early course of gout did not increase mortality.
. The influence of higher doses of allopurinol on gout patient mortality requires further study.
Introduction
Gout is the most common inflammatory arthritis, with a
rising worldwide prevalence [1]. The hallmark of initial
gout presentation is acute arthritis, but patients eventually
experience unremitting arthritis and joint deformity, and
tophus deposition may develop with long-standing hyper-
uricaemia [2]. Patients with gout suffer not only arthritis
but also cardiovascular, renal, metabolic and other
comorbidities [3]. Collectively, gout and associated
comorbidities lead to reduced overall survival [4].
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Allopurinol, with its primary mechanism of inhibiting the
activity of xanthine oxidase, is currently the first-line urate-
lowering treatment recommended in European guidelines
for gout. However, only around one-third of gout patients
receive allopurinol in the UK [5], and those are mainly on a
fixed dose of 300 mg, which is probably insufficient for
most patents. This is despite its reasonable safety profile
and probable additional beneficial effects on chronic dis-
eases such as hypertension, heart failure and stroke [6].
Despite generally being well tolerated, allopurinol has
been associated with StevenJohnson syndrome and
toxic epidermal necrolysis [7], which is potentially life
threatening. Although rare, this serious adverse event
has become one of the barriers to prescription of allopur-
inol for gout [8]. Whether the balance of these potential
benefits and risks can translate to any influence on sur-
vival in gout patients remains unclear. Therefore, we
undertook this study to assess the association between
allopurinol use and long-term mortality in patients with
gout using the UK Clinical Practice Research Data-link
(CPRD).
Methods
Data source
The CPRD is an anonymized database containing pro-
spectively collected medical records from 12 million
individuals in the UK. The database has been validated
for many diagnoses [9]. The database contains compre-
hensive information on patient demographics, date of
death, lifestyle factors, medical diagnoses, results of
laboratory tests and examinations, and medications pre-
scribed. In addition, the CPRD is also linked to external
data sources that provide information on secondary care
admissions, mortality and specific disease audits. The
study was approved by the Trent Multi-centre Research
Ethics Committee and the Independent Scientific Advisory
Committee.
Cohort
We used READ codes to identify incident gout patients in
the CPRD between 1995 and 1999. To be eligible as inci-
dent gout patients, participants had to be older than 20
years of age, have no evidence of gout or prescription for
urate-lowering treatment (mostly allopurinol) prior to the
time of diagnosis (index date) and have at least 1-year
registration prior to index date. The case definition was
based on physician diagnosis, using 18 Read codes indi-
cative of incident gout [10]. The validity of a gout diagnosis
in the CPRD has been demonstrated previously [11].
Exposure
We classified patients by exposure to allopurinol. A min-
imum of 6 months prescription of allopurinol was required
for assignment of allopurinol exposure. The prescription of
allopurinol largely lags behind the time of first diagnosis
[5]. Therefore, the completion of 6 months of allopurinol
therapy in relation to the date of gout diagnosis is likely to
vary considerably from person to person. In this study, we
utilized a landmark analysis to examine the effect of allo-
purinol exposure on all-cause mortality [12]. In a landmark
analysis, a fixed time after cohort entry was selected a
priori for conducting survival analysis. Only patients alive
at the date of the landmark were included in the analysis,
and treatment assignment was based on exposure prior
to the landmark date. Exposure was only evaluated
between the index date and the landmark time point
(exposure window), and the outcome was then evaluated
from this landmark time point. Two landmark time points
were determined a priori in this study, specifically at 1 and
at 3 years after initial gout diagnosis (supplementary Fig.
S1A, available at Rheumatology Online). Exposure status
was assigned for patients who were alive at the landmark
dates.
Covariates
Covariates included patient characteristics, lifestyle fac-
tors, 17 categories of comorbidity and drug treatments
(supplementary data, section on covariates, available at
Rheumatology Online). Only general practitioner records
occurring within the 5-year period before initial diagnosis
of gout were used to evaluate comorbidities and drug
treatment.
Outcomes
Patients were followed up until the date of death, transfer
out from a participating CPRD practice, or 31 December
2013, whichever was earliest (supplementary Fig. S1B,
available at Rheumatology Online). Mortality and date of
death were assessed using the main CPRD database. We
have undertaken a validation study comparing death
recordings in the CPRD and National Death Registry and
found the sensitivity, specificity, positive predictive value
and negative predictive value of a CPRD-recorded death
to be 0.99, 0.99, 0.93 and 1.00, respectively (supplemen-
tary Table S1, available at Rheumatology Online) [5].
Statistical analysis
We utilized propensity scorematching methods to
account for confounding by indication [13]. The propensity
score for allopurinol use represents the probability that a
patient is prescribed (56 months) allopurinol treatment.
We used logistic regression models to determine a pro-
pensity score for receiving at least 6 months allopurinol
during the exposure window (supplementary data, section
on propensity score adjustment analysis, available at
Rheumatology Online). In our primary analysis we
matched the allopurinol-exposed patients to unexposed
patients in a ratio of 1 to 1, based on the logit of the pro-
pensity score using callipers of width equal to 0.2 of the
S.D. of the logit of the propensity score. KaplanMeier
plots were used to estimate the cumulative probability of
survival. The hazard ratio for mortality was determined
using the Cox proportional hazards model. As a sensitivity
analysis, we included the entire cohort and adjusted for
the raw propensity score (supplementary data, section
on propensity score adjustment analysis, available at
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Rheumatology Online). All statistical analyses were per-
formed using SAS statistical software, version 9.3.
Results
Study population
Between January 1995 and December 1999, we identified
23 332 incident gout patients [men: 17 197 (73.91%)]. Due
to transferring out or death, 1385 patients were excluded
from the 1-year landmark analysis and 3783 patients were
excluded from the 3-year landmark analysis (supplemen-
tary Fig. S1A, available at Rheumatology Online).
Supplementary Table S2, available at Rheumatology
Online, summarizes and compares baseline characteris-
tics between included and excluded patients in the 1-year
and 3-year landmark analyses. In general, those excluded
were older and had a higher Charlson comorbidity index.
These differences were similar in the 1-year and 3-year
landmark analyses.
Matching
For the 1-year landmark analysis, we included 21 947
patients who were alive at 1 year from initial diagnosis
of gout. Among them, 1016 patients had at least 6
months of allopurinol prescription. No significant differ-
ences were found in variables included in the propensity
score calculation between allopurinol users and non-users
after matching, confirming the success of our matching
(Table 1). Supplementary Table S3, available at
Rheumatology Online, shows the comparison of variables
between allopurinol users and non-users in the 3-year
landmark analysis.
Outcomes after matching
As shown in Table 2, a total of 880 patients in the 1-year
landmark analysis and 2546 patients in the 3-year land-
mark analysis died during the follow-up period. No signifi-
cant difference was found for overall mortality rate
between allopurinol users and non-users in either the
1-year or the 3 year landmark analysis. There was no dif-
ference in survival based on KaplanMeier estimates
between allopurinol users and non-users in either the
1-year (log-rank test P= 0.84) or the 3-year landmark ana-
lysis (log-rank test P= 0.94) (supplementary Fig. S2, avail-
able at Rheumatology Online). Hazard ratios for all-cause
mortality were 0.99 (95% CI 0.87, 1.12) in the 1-year land-
mark analysis and 1.01 (95% CI 0.92, 1.09) in the 3-year
landmark analysis.
Discussion
This population-based study of incident gout patients
found that having at least 6 months use of allopurinol
within either 1 year or 3 years from initial diagnosis was
associated with neither a beneficial nor an adverse effect
on the long-term risk of all-cause mortality in patients who
survived to the date of the landmark time point. Our study
suggests that concern over an increased mortality risk
from taking allopurinol is unfounded. Given the many
established clinical benefits of allopurinol, such a neutral
effect on all-cause mortality supports the use of allopur-
inol early in the course of gout to prevent long-term com-
plications secondary to chronic hyperuricaemia.
This study used a well-defined population of incident
gout patients to determine whether allopurinol treatment
influences all-cause mortality. However, the date of allo-
purinol prescription largely lags behind the initial diagnosis
of gout [10]. Using diagnosis date as an index date to start
the follow-up for a delayed treatment in a cohort study is
prone to immortal time bias, which could confer a spuri-
ous survival advantage to the treatment group [14]. A
landmark analysis, as in our study, has been devised to
avoid this [12]. Another important factor that could influ-
ence comparison of survival function between patients
exposed and those not exposed to allopurinol is
confounding by indication, which is the result of
non-random allocation of treatment assignment. General
practitioners tended to prescribe allopurinol for patients of
more advanced age, more comorbidity and more poly-
pharmacy, who already have higher mortality. Therefore,
an unadjusted model demonstrated a higher mortality risk
in the allopurinol exposure group. To minimize this bias,
we used propensity score matching to balance the prob-
ability of being prescribed allopurinol in our exposure
window. Analyses based on both methods produced the
same neutral influence of allopurinol on long-term risk of
all-cause mortality.
Several previous studies have attempted to measure
the influence of allopurinol treatment on mortality, but
have reported conflicting results [1519]. These studies
in general ignored or only in part considered immortal
time bias and confounding by indication. Immortal time
bias generally causes spurious inflation of the beneficial
treatment effect due to the guaranteed period of survival
in the treatment group by design. Conversely, confound-
ing by indication generally favours the unexposed group,
because treated patients tend to have a poorer prognosis.
For example, Ma´lek et al. [15] reported poorer survival in
allopurinol-treated patients in a cohort of acute heart fail-
ure patients hospitalized in specialized heart centres, but
noted that allopurinol was an identifier of high-risk patients
who obviously had a particularly bad prognosis.
Immortal time bias is more difficult to identify than con-
founding by indication. For example, Luk et al. [17]
reported that allopurinol use was associated with a bene-
ficial effect on mortality in a hyperuricaemic population by
comparing survival of users and non-users. However, allo-
purinol users commenced follow-up from the time of inci-
dent allopurinol use, at which time they had survived from
the date of first documentation of hyperuricaemia,
whereas the follow-up of non-users could have been as
early as the date of first documentation of hyperuricaemia.
Although they matched the index date between users and
non-users, it did not mean that they matched the time
from diagnosis of hyperuricaemia to the index date be-
tween the two groups. Allopurinol users were still more
likely to have a spurious survival advantage because by
design they had to survive to the date of first allopurinol
www.rheumatology.oxfordjournals.org 2147
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TABLE 1 Comparison of patients exposed or not exposed to allopurinol within 1 year of initial diagnosis of gout before
and after matching
Exposure groups before matching Exposure groups after matching
Allopurinol
users
(n=1016)
Allopurinol
non-users
(n=20 931) P-value
Allopurinol
users
(n=1016)
Allopurinol
non-users
(n=1016) P-value
Age, median (interquartile
range), years 66 (5674) 61 (4973) <0.001 66 (5575) 66 (5674) 0.87
Gender
Men 665 (65.45) 15 611 (74.58) <0.001 665 (65.45) 655 (64.47) 0.64
Women 351 (34.55) 5320 (25.42) 351 (34.55) 361 (35.53)
BMI, kg/m2
<18.5 2 (0.20) 144 (0.69) <0.001 2 (0.20) 2 (0.20) 0.89
18.524.9 206 (20.28) 4472 (21.37) 206 (20.28) 223 (21.95)
25.029.9 375 (36.97) 8161 (38.99) 375 (36.97) 351 (34.55)
530 352 (34.65) 5537 (26.45) 352 (34.65) 357 (35.14)
Unknown 81 (7.97) 2617 (12.50 81 (7.97) 83 (8.17)
Smoking
Non-smoker 132 (12.99) 2391 (11.42) <0.001 132 (12.99) 135 (13.29) 0.72
Current smoker 96 (9.45) 1708 (8.16) 96 (9.45) 112 (11.02)
Ex-smoker 638 (62.80) 12 421(59.34) 638 (62.80) 613 (60.33)
Unknown 150 (14.76 4411 (21.07) 150 (14.76 156 (15.35)
Alcohol consumption, units/week
Never/ex-drinker 158 (15.55) 2141 (10.23) <0.001 158 (15.55) 167 (16.44) 0.80
Current 19 435 (42.81) 7986 (38.15) 435 (42.81) 444 (43.70)
Current 510 211 (20.77) 5070 (24.22) 211 (20.77) 188 (18.50)
Unknown 212 (20.87) 5734 (27.39) 212 (20.87) 217 (21.36)
Charlson comorbidity index
0 600 (59.06) 14 975 (71.54) <0.001 600 (59.06) 591 (58.17) 0.84
12 330 (32.48) 5054 (24.15) 330 (32.48) 341 (33.56)
34 82 (8.07) 865 (4.13) 82 (8.07) 81 (7.97)
54 4 (0.39) 37 (0.18) 4 (0.39) 3 (0.30)
Medications
Aspirin 295 (29.04) 3455 (16.51) <0.001 295 (29.04) 296 (29.13) 0.96
Statin 94 (9.25) 892 (4.23) <0.001 94 (9.25) 86 (8.46) 0.53
Diuretics 622 (61.22) 7401 (35.36) <0.001 622 (61.22) 617 (60.73) 0.82
Insulin 10 (0.98) 93 (0.44) 0.01 10 (0.98) 15 (1.48) 0.31
NSAID 773 (76.08) 15 272 (72.96) 0.03 773 (76.08) 789 (77.36) 0.50
Values are number (percentage) unless described otherwise.
TABLE 2 Comparison of patients exposed or not exposed to allopurinol within 3 years of initial diagnosis of gout before
and after matching
1-year landmark analysis 3-year landmark cohort
Allopurinol
users
(n=3540)
Allopurinol
non-users
(n=16009) P-value
Allopurinol
users
(n=3519)
Allopurinol
non-users
(n=3519) P-value
Follow-up, median (interquartile range), yearsa 10 (514) 10 (415) 0.72 9 (412) 10 (513) 0.25
Death 437 (43.01) 443 (43.60) 0.79 1281 (36.40) 1265 (35.95) 0.69
Mortality, died (%)
1 year from landmark 41 (4.07) 44 (4.37) 0.84 133 (3.82) 147 (4.22) 0.94
2 year from landmark 74 (7.40) 85 (8.52) 269 (7.84) 291 (8.48)
5 year from landmark 189 (19.64) 204 (21.19) 629 (19.08) 639 (19.30)
10 year from landmark 340 (37.61) 348 (38.31) 1088 (35.22) 1084 (35.01)
Values are number (percentage) unless described otherwise. aSince the time point of landmark.
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use in order to be assigned as cases. The more recent
study by Dubreuil et al. [19], using The UK Health
Improvement Network (THIN) database, also reported a
beneficial survival effect related to allopurinol use. Their
conclusions possibly suffered from immortal time bias,
because the necessity of allopurinol users to survive
from cohort entry (date of hyperuricaemia) to allopurinol
prescription was not required for non-users. Therefore,
without tackling immortal time bias by design (such as
using landmark analysis) or explicitly modelling the
timing of exposure (such as using time-dependent meth-
ods), a biased estimate can inevitably occur.
There are potential limitations to this study. First, there
is possible misclassification bias because the identifica-
tion of gout patients was based on diagnoses made by
general practitioners, rather than according to classifica-
tion criteria or to the gold standard of urate crystal iden-
tification. However, the validity of gout diagnosis in the
CPRD has been investigated and found to be high [11].
Second, the use of landmarks at 1 year and 3 years
means that our finding that allopurinol confers a neutral
effect on all-cause mortality only applies to patients who
are alive at these two landmarks time points. Third, the
dose of allopurinol used in primary care in the UK is pre-
dominantly <300 mg/day [20], and it is possible that
higher doses may be required to obtain a beneficial
effect on cardiovascular and renal outcomes. Ideally, a
randomized controlled trial is required to address this.
In conclusion, this propensity scorematched landmark
analysis in a population of incident gout patients in the UK
primary care setting found a neutral effect on the risk of
all-cause mortality from a minimal 6-month allopurinol use
at 1 year and at 3 years after initial diagnosis of gout. Our
study provides reassurance concerning the prescription of
allopurinol in gout patients early in their disease course to
prevent untoward consequences of chronic uncontrolled
hyperuricaemia.
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